Seroatlas · Human Serome Atlas

PRMT9

Protein arginine N-methyltransferase 9

Also known as: ANM9_HUMAN, FLJ46629, PRMT10

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q6P2P2
Gene
PRMT9
Ensembl
ENSG00000164169
Chromosome
4
Canonical length
845 aa
Protein class
Enzymes, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Microtubules,Cytosol

OverviewNCBI Gene

This gene encodes a type II methyltransferase. Post-translational modification of target proteins by PRMTs plays an important regulatory role in many biological processes, whereby PRMTs methylate arginine residues by transferring methyl groups from S-adenosyl-L-methionine to the guanidino nitrogen atoms of arginine. The protein encoded by this gene methylates spliceosome associated protein 145 to regulate alternative splicing and acts as a modulator of small nuclear ribonucleoprotein maturation. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Apr 2017]

Canonical amino-acid sequenceUniProt

845 residues, UniProt reviewed canonical sequence.

>Q6P2P2|PRMT9
     1  MSNSRPRSRR DAGGGAGAAG RDELVSRSLQ SAEHCLGVQD FGTAYAHYLL VLSLAPELKH
    61  DVKETFQYTL FRWAEELDAL SRIQDLLGCY EQALELFPDD EVICNSMGEH LFRMGFRDEA
   121  AGYFHKAVKL NPDFSDAKEN FYRVANWLVE RWHFIMLNDT KRNTIYNAAI QKAVCLGSKS
   181  VLDIGAGTGI LSMFAKKAGA HSVYACELSK TMYELACDVV AANKMEAGIK LLHTKSLDIE
   241  IPKHIPERVS LVVTETVDAG LFGEGIVESL IHAWEHLLLQ PKTKGESANC EKYGKVIPAS
   301  AVIFGMAVEC AEIRRHHRVG IKDIAGIHLP TNVKFQSPAY SSVDTEETIE PYTTEKMSRV
   361  PGGYLALTEC FEIMTVDFNN LQELKSLATK KPDKIGIPVI KEGILDAIMV WFVLQLDDEH
   421  SLSTSPSEET CWEQAVYPVQ DLADYWIKPG DHVMMEVSCQ DCYLRIQSIS VLGLECEMDV
   481  AKSFTQNKDL LSLGNEAELC SALANLQTSK PDAVEQTCIL ESTEIALLNN IPYHEGFKMA
   541  MSKVLSSLTP EKLYQTMDTH CQNEMSSGTG QSNTVQNILE PFYVLDVSEG FSVLPVIAGT
   601  LGQVKPYSSV EKDQHRIALD LISEANHFPK ETLEFWLRHV EDESAMLQRP KSDKLWSIII
   661  LDVIEPSGLI QQEIMEKAAI SRCLLQSGGK IFPQYVLMFG LLVESQTLLE ENAVQGTERT
   721  LGLNIAPFIN QFQVPIRVFL DLSSLPCIPL SKPVELLRLD LMTPYLNTSN REVKVYVCKS
   781  GRLTAIPFWY HMYLDEEIRL DTSSEASHWK QAAVVLDNPI QVEMGEELVL SIQHHKSNVS
   841  ITVKQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRMT9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.28
Highest tissue expression
11 nTPM

Expression across tissuesHPA

Tissue

  • ovary: 11 nTPM
  • adrenal gland: 9.3 nTPM
  • bone marrow: 8 nTPM
  • testis: 6.7 nTPM
  • parathyroid gland: 5.8 nTPM
  • thyroid gland: 5.4 nTPM

Single-cell type

  • innate lymphoid cells: 438 nCPM
  • pdcs: 346 nCPM
  • ovarian stromal cells: 261 nCPM
  • somatotrophs: 249 nCPM
  • lactotrophs: 209 nCPM
  • monocytes: 204 nCPM

Immune cell

  • eosinophil: 8.6 nTPM
  • memory B-cell: 7.5 nTPM
  • naive B-cell: 7.2 nTPM
  • naive CD4 T-cell: 7.1 nTPM
  • naive CD8 T-cell: 6.2 nTPM
  • basophil: 6.1 nTPM

Brain region

  • cerebellum: 8.3 nTPM
  • cerebral cortex: 6.9 nTPM
  • hippocampal formation: 6 nTPM
  • choroid plexus: 5.9 nTPM
  • hypothalamus: 5.6 nTPM
  • spinal cord: 5.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PRMT9.

Disease | GeneticClinVar

18 pathogenic / likely-pathogenic of 137 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.93
gnomAD pLI
0
DepMap mean gene effect
-0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PRMT9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRMT9 as an antibody target. Whether an autoantibody or antibody against PRMT9 could matter depends on whether native PRMT9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRMT9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRMT9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRMT9. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...